Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study
Xianchun Gao(National Clinical Research Center for Digestive Diseases), Yan Pan(National Clinical Research Center for Digestive Diseases), Wenjiao Li(Central South University), Han Liang(The University of Texas MD Anderson Cancer Center), Lei Shang, Yingtai Chen(Shanghai Jiao Tong University), Gang Ji(Xijing Hospital), Kaichun Wu(Xijing Hospital), Xiaoliang Gao(National Clinical Research Center for Digestive Diseases), Penghui Niu(Chinese Academy of Medical Sciences & Peking Union Medical College), Lulu Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongwei Li(National Clinical Research Center for Digestive Diseases), Kun Liu(Air Liquide (United Kingdom)), Ling Chen(Nanjing Drum Tower Hospital), Nannan Zhang(Lanzhou University), Yongzhan Nie(Xijing Hospital), Wanqing Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Renlong Li(Wenzhou Medical University), Zengshan Li(Xijing Hospital), Weili Han(National Clinical Research Center for Digestive Diseases), Qingchuan Zhao(City University of Hong Kong), Jingyu Deng(Tianjin Medical University Cancer Institute and Hospital), Junya Yan(National Clinical Research Center for Digestive Diseases), Yuanyuan Lu(National Clinical Research Center for Digestive Diseases), Haohao Zhang(National Clinical Research Center for Digestive Diseases)
Cited by 15
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Screening for gastric cancer in Asia: current evidence and practice
|The Lancet Oncology|2008|830
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
|Cancer Cell|2017|656